Author

K. E. Varley

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:cell type annotation· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Research Focus:chromatin & epigenetic regulation· 2 Research Focus:gene regulatory network inference· 2 Assay:ChIP-seq· 1 Research Focus:clustering· 1

Frequent Co-Authors

J. Gertz· 3 shared B. E. Welm· 2 shared J. M. Vahrenkamp· 2 shared K. P. Guillen· 2 shared M. E. Conway· 2 shared A. C. Beck· 1 shared A. J. Butterfield· 1 shared A. L. Welm· 1 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

J. Gertz

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

3D genomic analysis reveals novel enhancer-hijacking caused by complex structural alterations that drive oncogene overexpression

K. L. Mortenson, C. Dawes, E. R. Wilson, N. Patchen, H. E. Johnson, J. Gertz, S. D. Bailey, Y. Liu, K. E. Varley, X. Zhang

The paper introduces HAPI, a 3D genomics method, to identify enhancer hijacking in cancer cell lines, revealing novel oncogene activation mechanisms.

bioRxiv · Jan 23, 2024Cancer Biology

TXNIP loss expands Myc-dependent transcriptional programs by increasing Myc genomic binding

T.-Y. Lim, B. R. Wilde, M. L. Thomas, K. E. Murphy, J. M. Vahrenkamp, M. E. Conway, K. E. Varley, J. Gertz, D. E. Ayer

This study shows that TXNIP loss increases Myc genomic binding, expanding Myc-dependent transcriptional programs without increasing Myc levels or activity.

bioRxiv · Aug 4, 2022 · PreprintCancer Biology

A breast cancer patient-derived xenograft and organoid platform for drug discovery and precision oncology

K. P. Guillen, M. Fujita, A. J. Butterfield, S. D. Scherer, M. H. Bailey, Z. Chu, Y. S. DeRose, L. Zhao, E. Cortes-Sanchez, C.-H. Yang, J. Toner, G. Wang, Y. Qiao, X. Huang, J. A. Greenland, , A. L. Welm

The paper develops patient-derived xenografts and organoids for breast cancer to enable drug screening and precision oncology, showing efficacy of an FDA-approved drug in a clinical case.

bioRxiv · Feb 28, 2021 · PreprintCancer Biology

STAT3 and GR cooperate to drive basal-like triple negative breast cancer gene expression and proliferation.

M. E. Conway, J. M. McDaniel, J. M. Graham, K. P. Guillen, P. G. Oliver, S. L. Parker, P. Yue, J. Turkson, D. J. Buchsbaum, B. E. Welm, R. M. Myers, K. E. Varley

This study identifies GR and STAT3 as cooperative drivers of basal-like triple negative breast cancer gene expression and shows that their inhibition synergistically reduces cell proliferation.

bioRxiv · Aug 9, 2019Cancer Biology